Publications by authors named "Norbert Hollaender"

Claim this Profile
A
A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.
Norbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, Tommaso Stefanelli, Robert Zeiser

Bone Marrow Transplant· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Robert Zeiser, Nicola Polverelli, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Norbert Hollaender

N Engl J Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.
Norbert Hollaender, Juan Gonzalez-Maffe, Valentine Jehl

Biom J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.
Ali T Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Norbert Hollaender

Blood· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Norbert Hollaender

Blood· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.
Andrew Stein, Wenping Wang, Alison A Carter, Ovidiu Chiparus, Norbert Hollaender

BMC Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
Jennifer L Beaumont, Zeeshan Butt, Jeanfrancois Baladi, Robert J Motzer, Tomas Haas, Norbert Hollaender

Oncologist· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proof of concept phase II non-inferiority criterion.
Beat Neuenschwander, Nicolas Rouyrre, Norbert Hollaender, Emmanuel Zuber, Michael Branson

Stat Med· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Robert J Motzer, Bernard Escudier, Stephane Oudard, Thomas E Hutson, Camillo Porta, Norbert Hollaender

Cancer· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson, Camillo Porta, Norbert Hollaender

Lancet· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis